Wells Fargo
IOVA icon

Wells Fargo’s Iovance Biotherapeutics IOVA Stock Holding History

Wells Fargo’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,400
Closed -$6K – 6481
2019
Q4 		$6K Buy
+4,400
New +$100K ﹤0.01% 6003

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Wells Fargo's IOVA Position: Q1 2026 in Review

Wells Fargo increased its Iovance Biotherapeutics (IOVA) stake by 3.9% in Q1 2026, buying an estimated $250K and bringing the position to 2,071,524 shares worth $7.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2282.

Wells Fargo first reported a position in IOVA in Q2 2015 and has held it in 44 quarters since. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Wells Fargo held 2,071,524 shares of Iovance Biotherapeutics worth $7.27M as of Q1 2026.
  • Wells Fargo bought 78,187 Iovance Biotherapeutics shares in Q1 2026, an estimated $250K.
  • Iovance Biotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2282 holding.
  • Wells Fargo first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 44 quarters since.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.